EL7.AI
StocksMedium•27 July 2026•
1 min read

FDA Approves Freenome Blood Test for Colon Cancer with Abbott Launch Set for 2026

Key Facts

1The U.S. FDA approved Freenome's blood-based colorectal cancer screening test for older adults.
2Partner company Abbott plans to launch the test in the U.S. this fall.

In a move reflecting the rapid evolution of non-invasive medical diagnostics, the U.S. FDA has granted approval for Freenome's blood-based colorectal cancer screening test. This diagnostic tool specifically targets older adults, offering a significant alternative to traditional screening methods. According to reports, partner company Abbott plans to lead the commercial rollout, with a scheduled launch in the United States during the fall of 2026.

This regulatory milestone strengthens Abbott's position within the healthcare technology sector, as the partnership with Freenome enables access to advanced diagnostic capabilities. The approval paves the way for new revenue streams by providing patients with less invasive screening options. This development aligns with a broader industry trend toward adopting early detection solutions based on blood samples.

Regarding stock performance, ABT was priced at $103.1 at the close of July 24, 2026, following a trading range between $101.5 and $104.18. With no immediate healthcare-specific catalysts in the upcoming economic calendar, investors will likely focus on further updates regarding production and distribution timelines ahead of the anticipated launch next year.